

3800 S. Business Park Ave Marshfield, WI 54449 Phone: 715-387-0484

Fax: 715-384-3661

CMA-ISCA/PGxome Test Requisition Form

Person completing form Contact			Contact Inform	ation (phone o	or email)	Date of Request	
☐ Prob☐ Fam	hecklist (required): band (patient) specimen nily member specimen(s) – F althcare Provider Statement(•		 □ Clinic notes, summary, and/ or relevant medical records □ Pedigree with family medical health history □ Previous genetic testing results (where available) 			
		F	Proband In	formation			
Patient's Las	st (Family) Name	First Name		MI	Date Month of Birth:	Day Year	
Patient ID Co	ode	Date Collected:	Month	Day	Year	Gender: Male Female Other	
Specimen So	lood Extracted DNA Source:	Cultured Source:	Cells	Tissue Source:	Other:	GeoAncestry/Ethnicity	
Has patient l PreventionG		Has patient's relat PreventionGenetic		d at	Related to an ongoing pregnancy?	Bone marrow transplant or blood transfusion?	
∐Yes	□No	Yes No			Yes No	☐ Yes ☐ No	
If yes, PG ID		If yes, provide nar	ne & DOB:			If yes, date:	
	Test Selectio	n			Secondary Fir	ndinas	
	Test Selectio Chromosomal Microarray or for CMA)		finding variant	s in a minimum	e of Medical Genetics (ACI) of 56 genes be reported.	ndings MG) has recommended secondary Pathogenic or likely pathogenic ult unless a patient desires to "opt-	
	Chromosomal Microarray or	nly <u>(consent requi</u>	findings variant out."	s in a minimum s in these gene	e of Medical Genetics (ACI) of 56 genes be reported.	MG) has recommended secondary Pathogenic or likely pathogenic ult unless a patient desires to "optome	
	Chromosomal Microarray or for CMA) Exome Sequencing only (co	nly (consent requi	findings variant out." Additio e "opt-in.	s in a minimum is in these gene ACMO ACMO ACMO ACMO IN ACMO IN ACMO ACMO ACMO ACMO ACMO ACMO ACMO ACMO	e of Medical Genetics (ACI of 56 genes be reported. es will be reported by defau. G 56 OPT OUT – PGxo G 56 OPT OUT – CMAfindings can be reported if tional findings OPT IN	MG) has recommended secondary Pathogenic or likely pathogenic ult unless a patient desires to "optome -ISCA desired should the patient desire to I - PGxome	
	Chromosomal Microarray or for CMA) Exome Sequencing only (co PGxome) Chromosomal Microarray w.	nly (consent required for consent required for consent reguired for consent red for consent re	finding: variant out." Additio come opt-in. Details	s in a minimum is in these gene ACMC ACMC anal secondary in Additional Additi	e of Medical Genetics (ACI) of 56 genes be reported. It is will be reported by defaults will be reported by defaults. G 56 OPT OUT – PGXOG 56 OPT OUT – CMA-findings can be reported if tional findings OPT IN	MG) has recommended secondary Pathogenic or likely pathogenic ult unless a patient desires to "optome -ISCA desired should the patient desire to I - PGxome	
	Chromosomal Microarray or for CMA) Exome Sequencing only (copgxome) Chromosomal Microarray w. Sequencing (consent require) Chromosomal Microarray & concurrent (consent require)	onsent required for with reflex to Exome red for CMA & PGX Exome Sequencine ed for CMA & PGX Additional Fa	findings variant out." Additio "opt-in. opt-in. opt-i	s in a minimum is in these gene ACMC ACMC anal secondary in Additional Secondary in Additional Additional (required)	e of Medical Genetics (ACI of 56 genes be reported. es will be reported by defau. G 56 OPT OUT – PGxo G 56 OPT OUT – CMAfindings can be reported if tional findings OPT IN tional findi	MG) has recommended secondary Pathogenic or likely pathogenic ult unless a patient desires to "optome -ISCA desired should the patient desire to I - PGxome I - CMA-ISCA CMA-ISCA Healthcare Provider	
Name (Last,	Chromosomal Microarray or for CMA) Exome Sequencing only (copgxome) Chromosomal Microarray w. Sequencing (consent require) Chromosomal Microarray & concurrent (consent require)	onsent required for with reflex to Exome red for CMA & PGX ed for CMA & PG	findings variant out." Additio "opt-in. opt-in. opt-i	s in a minimum is in these gene ACMC ACMC anal secondary in Additional Secondary in Additional Additional (required)	e of Medical Genetics (ACI of 56 genes be reported. es will be reported by defau. G 56 OPT OUT – PGXOG 56 OPT OUT – CMAfindings can be reported if tional findings OPT IN tional findin	MG) has recommended secondary Pathogenic or likely pathogenic ult unless a patient desires to "optome -ISCA desired should the patient desire to I - PGxome I - CMA-ISCA CMA-ISCA Healthcare Provider	
Name (Last,	Chromosomal Microarray or for CMA) Exome Sequencing only (copgxome) Chromosomal Microarray w. Sequencing (consent require) Chromosomal Microarray & concurrent (consent require)	onsent required for with reflex to Exome red for CMA & PGX and for	findings variant out." Additio "opt-in. opt-in. opt-i	s in a minimum is in these gene ACMC ACMC anal secondary is Additional Secondary is Additional Secondary in Additional Seconda	e of Medical Genetics (ACI of 56 genes be reported. es will be reported by defau. G 56 OPT OUT – PGxo G 56 OPT OUT – CMAfindings can be reported if tional findings OPT IN tional findi	MG) has recommended secondary Pathogenic or likely pathogenic ult unless a patient desires to "optome -ISCA desired should the patient desire to I - PGxome I - CMA-ISCA CMA-ISCA Healthcare Provider	
Name (Last,	Chromosomal Microarray or for CMA) Exome Sequencing only (copgxome) Chromosomal Microarray we Sequencing (consent required concurrent (consent required for trio testing first)	onsent required for with reflex to Exome red for CMA & PGX ed for CMA & PG	findings variant out." Addition "opt-in. statem amily Men members' inform Samp	s in a minimum is in these gene ACMC ACMC anal secondary is Additional Secondary is Additional Secondary in Additional Seconda	e of Medical Genetics (ACI of 56 genes be reported. es will be reported by defau. G 56 OPT OUT – PGxo G 56 OPT OUT – CMAfindings can be reported if tional findings OPT IN tional findi	MG) has recommended secondary Pathogenic or likely pathogenic ult unless a patient desires to "optome -ISCA desired should the patient desire to I - PGxome I - CMA-ISCA CMA-ISCA Healthcare Provider uuired. Affected?	

CLIA#: 52D2065132 • CAP#: 7185561 • NPI: 1114140571 • AU ID: 1407125 Email: clinicaldnatesting@preventiongenetics.com Web: www.preventiongenetics.com



DISEASE PREVENTION THROUGH GENETIC TESTING

Office use only

3800 S. Business Park Ave Marshfield, WI 54449 Phone: 715-387-0484

Fax: 715-384-3661

Clinical Information

Indication for Testing								
A 00	A copy of a clinic summary/note is required. Other relevant Primary Indication:							
medical records, genetic testing results, and/or other results are					Developmental Delay		☐ Neurological	
encouraged to be included. Please also include a copy of the pedigree with family medical health history.					ysmorphic Features		Other (provide detail):	
Clinical information is critical for best interpretation of CMA-ISCA and/or PGxome data.				Multiple Congenital Anomalies				
	Additional Clinical Information							
						ll that apply)		
_	natal History		n, Hair, & Nails		<u>Cra</u>	niofacial (including hearing &		nitourinary (continued)
	Prematurity	Ш	Hyperpigmentation (describe)		Cleft lip		Renal agenesis or dysgenesis
	Intrauterine Growth		Hyponiamontation (describe)			•		Undescended testis
	Restriction (IUGR)	Ш	Hypopigmentation (describe)			Cleft palate		Renal tubulopathy
	Oligohydramnios		Unusual scarring			Craniosynostosis		Other
	Polyhydramnios		Connective tissue abnormalit	v		Dysmorphic features (describe)	End	locrine
	Cystic hygroma		(describe)	y		(46561156)		Diabetes mellitus
	Increased nuchal translucency (NT)		,			Ear malformation (describe)		Type I
	Other		Ichthyosis			,		○ Type II
	Ottlei		Rash			Microcephaly		Hypothyroidism
Grov	wth & Development		Blistering			Macrocephaly		Hyperthyroidism
	Failure to thrive		Lipoma (or other skin tumors)		Cataracts		Hypoparathyroidism
	Overgrowth		Hair abnormality (describe)			Coloboma (of eye)		Hyperparathyroidism
	Short stature		o Quality			Chronic progressive		Other
	Fine motor delay		QuantityDistribution			external ophthalmoplegia	NA-4	ala all'a
	Gross motor delay		 Pigmentation 			Ptosis		abolic
	Other		Nail abnormality (describe)			Abnormal vision (describe)		Ketosis
0	alitica O Debenden		o Size			Ontin atmosphere		Lactic acidosis
_	nition & Behavior		o Shape			Optic atrophy		Abnormal urine organic acids (describe)
	Speech delay		o Texture			Retinitis pigmentosa		(describe)
	Intellectual disability		Other			Abnormal eye movement		Abnormal plasma amino acids
	Moderate	Hen	natologic & Immunologic			Abnormal hearing (describe)		(describe)
	 Severe 		Anemia			Other		
	Learning disability		Neutropenia			Other		Abnormal acylcarnitine profile
	Autism spectrum disorder		Pancytopenia		Gas	strointestinal		(describe)
	ADHD		Immunodeficiency			Gastroschisis		Abnormal CPK
	Obsessive-compulsive		Other			Omphalocele		Other
	disorder					Pyloric stenosis		0.101
	Other	Neu	rological & Muscular			Anal atresia	Tun	<u>nors</u>
Mus	culoskeletal		Ataxia			Tracheoesophageal fistula		Tumor (describe)
	Club foot/feet		Chorea			Chronic diarrhea		
	Contractures		Seizures/Epilepsy			Chronic constipation		Age of onset
	Pterygium		Encephalopathy			Gastrointestinal reflux		Other
	Diaphragmatic hernia		Hypotonia			Recurrent vomiting	Add	litional Testing (please attach
	Limb anolamly		Hypertonia			Hirschsprung disease		ies of results if available)
	Polydactyly		Spasticity			Chronic intestinal pseudo-		Chromosomes (karyotype), result :
	Syndactyly		Dystonia		_	obstruction		
	Scoliosis		Muscle weakness/atrophy			Other		
	Kyphosis		Exercise intolerance		<u>Ge</u> r	nitourinary		Chromosomal Microarray (CMA),
	Vertebral anomaly		Structural brain			Ambiguous genitalia		result:
	Other		abnormalities/abnormal brain imaging (describe)			Cryptochidism		
	Cuici					Hydronephrosis	Oth	er molecular studies, results :
			Other			Hypospadias		
						Kidney malformation		
		•				•		

CLIA#: 52D2065132 • CAP#: 7185561 • NPI: 1114140571 • AU ID: 1407125 $\underline{Email: \underline{clinicaldnatesting@preventiongenetics.com}} \ Web: \underline{www.preventiongenetics.com} \ Web: \underline{www.preventiongenetics.com}$



Institution

Office use only 3800 S. Business Park Ave Marshfield, WI 54449 Phone: 715-387-0484 Fax: 715-384-3661

Provider/Laboratory Contact Information

Provider Information

- Our preferred method of report transmission is email (via ShareFile). Please provide an email address when possible.
- If you have additional specific reporting requests, please indicate them below.

Address (please include city, state, cour	ntry & postal code)				
Requesting Physician (First, Last, Degre	e)	Requesting Genetic Counselor (First, Last, Degree)			
Phone Number	NPI#:	Phone Number	NPI#		
Email		Email			
Test Reporting In	structions	Test Reporting Instructions			
Our preferred method of report transmi	ssion is email (via ShareFile)	Our preferred method of report transm	ission is email (via ShareFile)		
Email (via ShareFile): use above		Email (via ShareFile): use above			
DO NOT email results. Instead, send v	via fax (provide fax #):	DO NOT email results. Instead, send	via fax (provide fax #):		
<u> </u>	. ,		. ,		
Sendout Laboratory (Compl	ete only if report needed)	Other			
Sendout Laboratory (Compl Laboratory & Contact Person	ete only if report needed)	Other Contact Name			
	ete only if report needed)				
	ete only if report needed)				
Laboratory & Contact Person Address	ete only if report needed)	Contact Name Address			
Laboratory & Contact Person	ete only if report needed)	Contact Name			
Laboratory & Contact Person Address Phone Number	ete only if report needed)	Contact Name Address Phone Number			
Laboratory & Contact Person Address	ete only if report needed)	Contact Name Address			
Laboratory & Contact Person Address Phone Number Email		Contact Name Address Phone Number Email	structions		
Laboratory & Contact Person Address Phone Number	structions	Contact Name Address Phone Number			
Laboratory & Contact Person Address Phone Number Email Test Reporting Institute Our preferred method of report transmin	structions	Contact Name Address Phone Number Email Test Reporting In Our preferred method of report transmi			
Laboratory & Contact Person Address Phone Number Email Test Reporting Ins	structions	Contact Name Address Phone Number Email Test Reporting In			
Laboratory & Contact Person Address Phone Number Email Test Reporting Institute Our preferred method of report transmin	structions	Contact Name Address Phone Number Email Test Reporting In Our preferred method of report transmi			
Address Phone Number Email Test Reporting Ins Our preferred method of report transmit Email (via ShareFile): use above	structions ssion is email (via ShareFile)	Contact Name Address Phone Number Email Test Reporting In Our preferred method of report transmi Email (via ShareFile): use above	ission is email (via ShareFile)		
Laboratory & Contact Person Address Phone Number Email Test Reporting Institute Our preferred method of report transmin	structions ssion is email (via ShareFile)	Contact Name Address Phone Number Email Test Reporting In Our preferred method of report transmi	ission is email (via ShareFile)		
Address Phone Number Email Test Reporting Ins Our preferred method of report transmit Email (via ShareFile): use above	structions ssion is email (via ShareFile)	Contact Name Address Phone Number Email Test Reporting In Our preferred method of report transmi Email (via ShareFile): use above	ission is email (via ShareFile)		
Address Phone Number Email Test Reporting Inst Our preferred method of report transmit Email (via ShareFile): use above	structions ssion is email (via ShareFile)	Contact Name Address Phone Number Email Test Reporting In Our preferred method of report transmi Email (via ShareFile): use above	ission is email (via ShareFile)		

CLIA#: 52D2065132 ● CAP#: 7185561 ● NPI: 1114140571 ● AU ID: 1407125 Email: <u>clinicaldnatesting@preventiongenetics.com</u> Web: <u>www.preventiongenetics.com</u>



3800 S. Business Park Ave Marshfield, WI 54449 Phone: 715-387-0484

Fax: 715-384-3661

Billing Instructions

 1. Please choose one of the the line institutional line included line insurance 2. Provide all information for the line included line insurance 		
Note: Patient testing will be delayed until all of the If Individual/Insurance billing information is incompublie in progress will be billed for the amount of we collected in New York, a New York State Non-Permit before testing will proceed.	plete, the institution will lork completed up to that	be billed. Tests that are cancelled point. If the patient's specimen is
1. Institutional Billing (Preferre	d)	
Billing Institution	•	PO Number
Contact	Phone Number(s)	Email
Address		
City Sta		Zip
Email Invoice	Copy of Test Report(s) for L Email (via ShareFile):	
Email Address:	Other (please specify):	_ same as previous
	United (please specify).	
2. Individual Billing		
Responsible Party's Name (Must be 18 years or older)	Phone Number(s)	Email
Address		
		_
City Sta		Zip
ACCEPTANCE OF FINANCIAL RESPONSIBILITY FOR Note: Prevention Genetics cannot proceed with testing of the specim		
My signature below indicates that I accept financial responsibility for a	all fees associated with this gene	etic testing order.
Signature of Responsible Party Printed Na	me of Responsible Party	 Date
COMPLETE THE FOLLOWING FOR CREDIT CARD Credit Card # / (VISA, Discover, or Mastercard only)	PAYMENT Expiration Date	3-Digit Security Code
My signature below authorizes PreventionGenetics to charge my c	redit card for services for whic	ch I am responsible.

4 | P a g e

Date:

CLIA#: 52D2065132 • CAP#: 7185561 • NPI: 1114140571 • AU ID: 1407125 Email: clinicaldnatesting@preventiongenetics.com Web: www.preventiongenetics.com

Signature:



3800 S. Business Park Ave Marshfield, WI 54449 Phone: 715-387-0484

Fax: 715-384-3661

Billing Instructions

3. Insurance Billing							
We will file an insurance claim on behalf of the patient with any commercial insurance company. However, the claim will be submitted as an "out of network" service provider. We are in network (contracted provider) with a limited number of insurance plans (see website). The patient is responsible for any portion of the test fee not covered by the insurance company for any reason including, but not limited to, co-payments, co-insurance, unmet deductibles, or non-covered services.							
Responsible Party's Name (Must be 18)		Phone Number(s)		Email			
Responsible Party Address							
City	Zip						
Policyholder Name (Required)	cyholder Name (Required) Please indicate the type of insurance: (Circle One)			Primary Insura	nce Company Name (Required)		
	Private / Medicare /	WI Medicaid					
Insurance Company Address- Claims							
City	City State				Zip		
ICD-10 Codes (Required)	Policy ID#		Group #		Authorization #		
Please attach the following: Note: PreventionGenetics cannot proceed with testing of the specimen until all information is received. NPI # of Requesting Physician Letter of Medical Necessity Medicare - signed ABN Form completed IN FULL Relevant Medical Records Copy of both sides of Insurance Card NY Non-permitted lab approval letter (if specimen collected in NY) Authorization number or letter of agreement from insurance company (if available). If not included, we will routinely perform pre-verification prior to initiating testing & will relay information to ordering provider.							
AUTHORIZATION TO ASSIGN BENEFITS AND ACCEPT FINANCIAL RESPONSIBILITY FOR MY ACCOUNT Note: PreventionGenetics cannot proceed with testing of the specimen without a signature below.							
I authorize PreventionGenetics to release information received including, without limitation, medical information, which includes laboratory test results, such as genetic tests results, to my health plan/insurance carrier and its authorized representatives. I further authorize insurance payments directly to PreventionGenetics for the services rendered. I understand my health plan/insurance/Medicare/Medicaid carrier may not approve and reimburse my medical genetic services in full due to usual and customary rate limits, benefit exclusions, coverage limits, lack of authorization, medical necessity or otherwise. I understand I am financially responsible for fees not paid in full by my insurer, co-payments, and policy deductibles except where my liability is limited by contract or State and Federal law. I agree to help PreventionGenetics resolve any insurance claim issues.							
Signature of Patient or Guardian	Printed Na	me of Patient o	r Guardian	_	Date		
					ty Code		
My signature below authorizes PreventionGenetics to charge my credit card for services for which I am responsible upon completion of insurance processing.							
Signature:				Date:			

CLIA#: 52D2065132 • CAP#: 7185561 • NPI: 1114140571 • AU ID: 1407125 Email: <u>clinicaldnatesting@preventiongenetics.com</u> Web: <u>www.preventiongenetics.com</u>



3800 S. Business Park Ave Marshfield, WI 54449 Phone: 715-387-0484

Fax: 715-384-3661

Specimen and Shipping Instructions

Specimen Requirements

WHOLE BLOOD: Collect 3-5 ml of whole blood in EDTA (purple top tube) or ACD (yellow top tube), minimum 1 ml for small infants.

DNA: Send in screw cap tube at least 10 µg of purified DNA at a concentration of at least 100 µg/ml (indicate concentration on tube label) for exome only.

SALIVA, CELL CULTURE, & FRESH, FROZEN TISSUE: Please contact us.

Shipping/Handling Instructions

Please label all specimen containers with the patient name, date of birth and/or ID number. At least two identifiers should be listed on specimen containers. We accept specimen deliveries Monday-Saturday for all specimen types except cell cultures. Cell culture deliveries are routinely accepted Monday-Thursday and require advance notice of arrival. If a Friday delivery is necessary please contact us to make arrangements. Holiday schedules will be posted on our home page at least one week prior to major holidays.

BLOOD: Do not freeze. During hot weather, include a frozen ice pack in the shipping container. Place a paper towel or other thin material between the ice pack and the blood tube. In cold weather include an unfrozen ice pack in the shipping container as insulation. At room temperature, blood specimen is stable for up to 48 hours. If refrigerated, blood specimen is stable for up to one week.

DNA: DNA may be shipped at room temperature. Label the tube with the composition of the solute, DNA concentration as well as the patient name, date of birth, and/or ID number. We only accept genomic DNA for testing. We do NOT accept products of whole genome amplification reactions or other amplification reactions.

CELL CULTURES: We are NOT able to culture cells. Send confluent flasks of cultured cells in insulated, shatterproof container overnight.

Address	Testing Kits
Diagnostic Lab PreventionGenetics 3800 S. Business Park Ave. Marshfield, WI 54449 USA	Clinical testing kits with prepaid return shipping are now available for our U.S. clients. We are able to provide Clinical Testing Kits to our international clients without the return postage at this time. To order kits, submit requests through our Electronic Order Form or contact our Client Service Representatives at 715-387-0484, ext. 0.

DNA Genotyping Panel

For quality control purposes, the PreventionGenetics DNA Genotyping Panel is performed on all clinical specimens. Genotyping results are *not* included in test reports.

DNA Banking

DNA Banking has a reduced price of \$98 for patients if clinical testing is also being performed with us. For DNA Banking, see our DNA Banking Process and DNA Banking Forms. For questions related to DNA Banking, contact our DNA Banking Director at 715-387-0484, ext. 151 or email dnabanking@preventiongenetics.com.

Contact Us

For additional questions or concerns, please contact our Client Service Representatives at 715-387-0484, ext. 0 or our Genetic Counseling Team at ext. 208 or clinicaldnatesting@preventiongenetics.com.

> CLIA#: 52D2065132 • CAP#: 7185561 • NPI: 1114140571 • AU ID: 1407125 Email: clinicaldnatesting@preventiongenetics.com Web: www.preventiongenetics.com